The MCP-1 increase was significantly lower in the treated groups compared to the BD group: Coversin group FC 77 (33–121) (p = 0.0006), anti-CD14 group FC 59 (29–90) (p < 0.0001) and the dual treatment group FC 76 (51–100) (p = 0.003) (Fig. 4D). Here, CCL2 is linked to Behcet disease.